Journal article
Genetic dissection of the pre-eclampsia susceptibility locus on chromosome 2q22 reveals shared novel risk factors for cardiovascular disease
MP Johnson, SP Brennecke, CE East, TD Dyer, LT Roten, JM Proffitt, PE Melton, MH Fenstad, T Aalto-Viljakainen, K Mäkikallio, S Heinonen, E Kajantie, J Kere, H Laivuori, R Austgulen, J Blangero, EK Moses, A Pouta, K Kivinen, E Ekholm Show all
Molecular Human Reproduction | Published : 2013
Abstract
Pre-eclampsia is an idiopathic pregnancy disorder promoting morbidity and mortality to both mother and child. Delivery of the fetus is the only means to resolve severe symptoms. Women with pre-eclamptic pregnancies demonstrate increased risk for later life cardiovascular disease (CVD) and good evidence suggests these two syndromes share several risk factors and pathophysiological mechanisms. To elucidate the genetic architecture of pre-eclampsia we have dissected our chromosome 2q22 susceptibility locus in an extended Australian and New Zealand familial cohort. Positional candidate genes were prioritized for exon-centric sequencing using bioinformatics, SNPing, transcriptional profiling and ..
View full abstractGrants
Awarded by AT and T Foundation
Funding Acknowledgements
M.P.J. is supported, in part, by an American Heart Association National Scientist Development grant [09SDG2350008]. This work was supported by the National Institutes of Health [HD049847 to E.K.M., S.P.B. and J.B., MH059490 to J.B., S10 RR029392 to J.B.]; the Semp Russ Foundation of the San Antonio Area Foundation (to M.P.J.); and the Texas Biomed Forum (to M.P.J.). The AT&T Genomics Computing Center at Texas Biomed is supported by the AT&T Foundation. The Norwegian cohort study was supported by the Liaison Committee of Central Norway Regional Health Authority and NTNU (to L. T. R. and M. H. F.) and the Functional Genomic Programme (FUGE) of the Norwegian Research Council (to R. A.). The FINNPEC study was supported by Jane and Aatos Erkko Foundation, Paivikki and Sakari Sohlberg Foundation, Academy of Finland, Research Funds of the University of Helsinki, Government Special Subsidiary for Health Sciences (EVO funding) at Helsinki and Uusimaa Hospital District. Novo Nordisk Foundation, Finnish Foundation for Pediatric Research, Emil Aaltonen Foundation and Sigrid Juselius Foundation. This investigation was conducted, in part, in facilities constructed with support from Research Facilities Improvement Program [grants C06 RR13556 and C06 RR017515] from the NIH.